Impact evaluation of a Health and Social Protection Scheme for micro-entrepreneurs in Ouagadougou, Burkina Faso

Last registered on November 12, 2021


Trial Information

General Information

Impact evaluation of a Health and Social Protection Scheme for micro-entrepreneurs in Ouagadougou, Burkina Faso
Initial registration date
November 10, 2021

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
November 12, 2021, 5:55 PM EST

First published corresponds to when the trial was first made public on the Registry after being reviewed.



Primary Investigator

University of Bordeaux

Other Primary Investigator(s)

PI Affiliation
Heidelberg Institute of Global Health (HIGH)

Additional Trial Information

On going
Start date
End date
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
This cluster randomized controlled trial aims to understand better the impact of health insurance on 2,000 women and their families in Ouagadougou, Burkina Faso. This RCT takes place in a Burkinabe microfinance institution (Yikkri), collaborating with a social insurance association (Tond Laafi). The program under study is a health and social protection system aiming at improving access to healthcare for micro-entrepreneurs and their families through health insurance, medico-social accompaniment and preventive health.
Three-wave surveys evaluate the health behavior, household vulnerability, working status, willingness to pay for health insurance, risk aversion and time preferences of these households, as well as social norms regarding women's access to healthcare and intra-household decision power. In January and February 2020, before the introduction of the health insurance program, a baseline survey was administrated to 2,000 micro-insurance beneficiaries. In June 2020, a midline (phone-)survey has been implemented on half of the participants to capture the potential impact of the Covid-19 crisis on health, labor and financial behavior. In September 2020, the health insurance program started for half of the sample while the others (control group) will be prevented from subscribing to it. The end-line quantitative and qualitative survey is planned for January and February 2022.
External Link(s)

Registration Citation

BOUTIN, DELPHINE and Laurène Petitfour. 2021. "Impact evaluation of a Health and Social Protection Scheme for micro-entrepreneurs in Ouagadougou, Burkina Faso." AEA RCT Registry. November 12.
Experimental Details


Mandatory health and social protection system including health insurance, medico-social accompaniment and preventive health.
Intervention Start Date
Intervention End Date

Primary Outcomes

Primary Outcomes (end points)
Health behavior/ use of healthcare, Women empowerment
Primary Outcomes (explanation)
Health behavior/ use of healthcare: time or delay to use healthcare centers, use of informal medicine, catastrophic spending cuts
Women empowerment: final say, intimate partner violence, gender social norms regarding health behavior (vignettes)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
The microfinance agency consists of about 200 groups of 40 people. We randomly selected 100 groups and then randomly selected 20 people from each group so that we had a sample frame of 2,000 people participating in the trial.
All members of the agency were then told that (mandatory) health insurance would be introduced in September 2020, but that for logistical reasons, only half of the members would receive it. It was indicated that the other half would receive it in January 2022. The selection of the 50 treated and controlled groups was random. All treated and control members respected their assignment group.
Experimental Design Details
Randomization Method
Randomization done in office by a computer
Randomization Unit
Groups of micro-entrepreneurs
Was the treatment clustered?

Experiment Characteristics

Sample size: planned number of clusters
100 groups
Sample size: planned number of observations
2000 individuals
Sample size (or number of clusters) by treatment arms
1000 individuals (20 per group) for treatment
1000 individuals (20 per group) for control
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)

Institutional Review Boards (IRBs)

IRB Name
Comité d'éthique pour la recherche en science de la santé (IRSS)
IRB Approval Date
IRB Approval Number


Post Trial Information

Study Withdrawal

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information


Is the intervention completed?
Data Collection Complete
Data Publication

Data Publication

Is public data available?

Program Files

Program Files
Reports, Papers & Other Materials

Relevant Paper(s)

Reports & Other Materials